241 related articles for article (PubMed ID: 11454998)
1. Gelatinous ascites: a cytohistologic study of pseudomyxoma peritonei in 67 patients.
Jackson SL; Fleming RA; Loggie BW; Geisinger KR
Mod Pathol; 2001 Jul; 14(7):664-71. PubMed ID: 11454998
[TBL] [Abstract][Full Text] [Related]
2. Disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis. A clinicopathologic analysis of 109 cases with emphasis on distinguishing pathologic features, site of origin, prognosis, and relationship to "pseudomyxoma peritonei".
Ronnett BM; Zahn CM; Kurman RJ; Kass ME; Sugarbaker PH; Shmookler BM
Am J Surg Pathol; 1995 Dec; 19(12):1390-408. PubMed ID: 7503361
[TBL] [Abstract][Full Text] [Related]
3. Mucinous tumors arising in ovarian mature cystic teratomas: relationship to the clinical syndrome of pseudomyxoma peritonei.
Ronnett BM; Seidman JD
Am J Surg Pathol; 2003 May; 27(5):650-7. PubMed ID: 12717249
[TBL] [Abstract][Full Text] [Related]
4. Ovarian mature teratomas with mucinous epithelial neoplasms: morphologic heterogeneity and association with pseudomyxoma peritonei.
McKenney JK; Soslow RA; Longacre TA
Am J Surg Pathol; 2008 May; 32(5):645-55. PubMed ID: 18344868
[TBL] [Abstract][Full Text] [Related]
5. Patients with pseudomyxoma peritonei associated with disseminated peritoneal adenomucinosis have a significantly more favorable prognosis than patients with peritoneal mucinous carcinomatosis.
Ronnett BM; Yan H; Kurman RJ; Shmookler BM; Wu L; Sugarbaker PH
Cancer; 2001 Jul; 92(1):85-91. PubMed ID: 11443613
[TBL] [Abstract][Full Text] [Related]
6. Pseudomyxoma peritonei: new concepts in diagnosis, origin, nomenclature, and relationship to mucinous borderline (low malignant potential) tumors of the ovary.
Ronnett BM; Shmookler BM; Sugarbaker PH; Kurman RJ
Anat Pathol; 1997; 2():197-226. PubMed ID: 9575376
[TBL] [Abstract][Full Text] [Related]
7. [Histologic classification and prognostic implication of pseudomyxoma peritonei].
Guo AT; Wei LX; Song X
Zhonghua Bing Li Xue Za Zhi; 2007 Jul; 36(7):474-9. PubMed ID: 17845762
[TBL] [Abstract][Full Text] [Related]
8. Pseudomyxoma peritonei: clinical pathological and biological prognostic factors in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC).
Baratti D; Kusamura S; Nonaka D; Langer M; Andreola S; Favaro M; Gavazzi C; Laterza B; Deraco M
Ann Surg Oncol; 2008 Feb; 15(2):526-34. PubMed ID: 18043976
[TBL] [Abstract][Full Text] [Related]
9. [Prognostic value of clinical and pathological characteristics in 48 women with pseudomyxoma peritonei].
Lu YY; Guo AT; Liu AJ; Shi HY
Zhonghua Fu Chan Ke Za Zhi; 2013 Aug; 48(8):595-601. PubMed ID: 24199925
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of single isolated cells with decreased E-cadherin expression in pseudomyxoma peritonei.
Koh YW; Jun SY; Kim KR
Pathol Int; 2014 Apr; 64(4):164-72. PubMed ID: 24750186
[TBL] [Abstract][Full Text] [Related]
11. Histopathologic analysis in 46 patients with pseudomyxoma peritonei syndrome: failure versus success with a second-look operation.
Yan H; Pestieau SR; Shmookler BM; Sugarbaker PH
Mod Pathol; 2001 Mar; 14(3):164-71. PubMed ID: 11266521
[TBL] [Abstract][Full Text] [Related]
12. Significance of epithelial cell clusters in pseudomyxoma peritonei.
Badyal RK; Khairwa A; Rajwanshi A; Nijhawan R; Radhika S; Gupta N; Dey P
Cytopathology; 2016 Dec; 27(6):418-426. PubMed ID: 27121698
[TBL] [Abstract][Full Text] [Related]
13. Management of pseudomyxoma peritonei by cytoreduction+HIPEC (hyperthermic intraperitoneal chemotherapy): results analysis of a twelve-year experience.
Vaira M; Cioppa T; DE Marco G; Bing C; D'Amico S; D'Alessandro M; Fiorentini G; DE Simone M
In Vivo; 2009; 23(4):639-44. PubMed ID: 19567401
[TBL] [Abstract][Full Text] [Related]
14. Pseudomyxoma peritonei--two novel orthotopic mouse models portray the PMCA-I histopathologic subtype.
Flatmark K; Reed W; Halvorsen T; Sørensen O; Wiig JN; Larsen SG; Fodstad Ø; Giercksky KE
BMC Cancer; 2007 Jun; 7():116. PubMed ID: 17603904
[TBL] [Abstract][Full Text] [Related]
15. MUC2 is a molecular marker for pseudomyxoma peritonei.
O'Connell JT; Hacker CM; Barsky SH
Mod Pathol; 2002 Sep; 15(9):958-72. PubMed ID: 12218214
[TBL] [Abstract][Full Text] [Related]
16. Pseudomyxoma peritonei of appendiceal origin: a clinicopathologic analysis of 101 patients uniformly treated at a single institution, with literature review.
Bradley RF; Stewart JH; Russell GB; Levine EA; Geisinger KR
Am J Surg Pathol; 2006 May; 30(5):551-9. PubMed ID: 16699309
[TBL] [Abstract][Full Text] [Related]
17. Appendiceal neoplasms and pseudomyxoma peritonei: a population based study.
Smeenk RM; van Velthuysen ML; Verwaal VJ; Zoetmulder FA
Eur J Surg Oncol; 2008 Feb; 34(2):196-201. PubMed ID: 17524597
[TBL] [Abstract][Full Text] [Related]
18. Pseudomyxoma peritonei. A clinicopathologic study of 19 cases with emphasis on site of origin and nature of associated ovarian tumors.
Prayson RA; Hart WR; Petras RE
Am J Surg Pathol; 1994 Jun; 18(6):591-603. PubMed ID: 8179074
[TBL] [Abstract][Full Text] [Related]
19. COX-2 expression in pseudomyxoma peritonei.
Gatalica Z; Loggie B
Cancer Lett; 2006 Nov; 244(1):86-90. PubMed ID: 16427185
[TBL] [Abstract][Full Text] [Related]
20. Pseudomyxoma peritonei of 92 Chinese patients: clinical characteristics, pathological classification and prognostic factors.
Guo AT; Li YM; Wei LX
World J Gastroenterol; 2012 Jun; 18(24):3081-8. PubMed ID: 22791943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
